The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore

Por Lacey, L F, Gane, E
Publicado em 2007

Costas DFC-Based Random Stepped Wideband Waveform for Interference Countermeasure in SAR Imagery

Por GanE Dai, Lei Zhang, Sha Huan
Publicado em 2022-04-01

Liver transplantation for haemophiliacs with hepatitis C cirrhosis.

Por McCarthy, M, Gane, E, Pereira, S, Tibbs, C J, Heaton, N, Rela, M, Hambley, H, Williams, R
Publicado em 1996

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B

Por Wang, Y, Thongsawat, S, Gane, E J, Liaw, Y-F, Jia, J, Hou, J, Chan, H L Y, Papatheodoridis, G, Wan, M, Niu, J, Bao, W, Trylesinski, A, Naoumov, N V
Publicado em 2013

Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial

Por Wade, A. J., Doyle, J. S., Gane, E., Stedman, C., Draper, B., Iser, D., Roberts, S. K., Kemp, W., Petrie, D., Scott, N., Higgs, P., Agius, P. A., Roney, J., Stothers, L., Thompson, A. J., Hellard, M. E.
Publicado no Trials (2018)

A183 SOFOSBUVIR-BASED ALL-ORAL REGIMENS FOR PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 3 INFECTION: INTEGRATED ANALYSIS OF FIVE CLINICAL STUDIES

Por Foster, G R, Zeuzem, S, Gane, E J, Stedman, C, Feld, J, Mangia, A, Agarwal, K, Swain, M, Mir, H, Troke, P, Llewellyn, J, Natha, M, Kreter, B, Zhang, J, McNally, J, Brainard, D, Strasser, S, Pianko, S
Publicado no J Can Assoc Gastroenterol (2018)

A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (...

Por Conway, B, Dore, G J, Altice, F, Litwin, A, Grebely, J, Dalgard, O, Gane, E J, Shibolet, O, Luetkemeyer, A, Nahass, R, Peng, C, Gendrano, I, Huang, H, Chen, E, Nguyen, B, Wahl, J, Barr, E, Robertson, M, Platt, H
Publicado no J Can Assoc Gastroenterol (2018)